All In MedTech

FDA Clearance Tracker · P990027-S021

TECHNOLAS TENEO™ 317 (MODEL 2) Excimer Laser System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 22, 2023

Approved

Time to decision

293 days

Received Feb 2, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P990027-S021
Device name
TECHNOLAS TENEO™ 317 (MODEL 2) Excimer Laser System
Applicant location
MüNchen
Received
Feb 2, 2023
Decided
Nov 22, 2023
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P990027

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LZS

FDA's approval statement

As written in FDA's record.

Approval for the TECHNOLAS TENEO 317 MODEL 2 Excimer Laser System. This device is indicated for laser-assisted in situ keratomileusis (LASIK) in:• Patients for the reduction or elimination of myopic astigmatism up to -10.00 D MRSE, with sphere between -1.00 D to -10.0 D and cylinder between 0.00 and -3.00 D; • Patients who are 22 years of age or older;• Patients must have a stable refraction in the last 12 months, as documented by previous clinical recordings, i.e., the spherical and cylindrical portions of the manifest distance refraction have not progressed at a rate of more than 0.50 D per year prior to the baseline examination in the eye(s) to be treated.

Source documents

Other decisions for Technolas Perfect Vision GmbH

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.